Evidence map›Paper›PMID 27094326›Full record

ArticlemBio2016

Chemical Genomics Identifies the PERK-Mediated Unfolded Protein Stress Response as a Cellular Target for Influenza Virus Inhibition.

Sara Landeras-Bueno, Yolanda Fernández, Ana Falcón, Juan Carlos Oliveros, Juan Ortín

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Human long noncoding RNAJournal of virology · 2025
    Article
  4. Article
  5. Human long noncoding RNA,bioRxiv : the preprint server for biology · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. The integrated stress response in pulmonary disease.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sara Landeras-BuenoDepartamento de Biología Molecular y Celular, Centro Nacional de Biotecnología (CSIC), Madrid, Spain Ciber de Enfermedades Respiratorias (ISCIII), Madrid, Spain.
Yolanda FernándezDepartamento de Biología Molecular y Celular, Centro Nacional de Biotecnología (CSIC), Madrid, Spain Ciber de Enfermedades Respiratorias (ISCIII), Madrid, Spain.
Ana FalcónDepartamento de Biología Molecular y Celular, Centro Nacional de Biotecnología (CSIC), Madrid, Spain Ciber de Enfermedades Respiratorias (ISCIII), Madrid, Spain.
Juan Carlos OliverosServicio de Genómica Computacional, Centro Nacional de Biotecnología (CSIC), Madrid, Spain.
Juan OrtínDepartamento de Biología Molecular y Celular, Centro Nacional de Biotecnología (CSIC), Madrid, Spain Ciber de Enfermedades Respiratorias (ISCIII), Madrid, Spain jortin@cnb.csic.es.
Centro Nacional de Biotecnología · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledInfluenza A viruses generate annual epidemics and occasional pandemics of respiratory disease with important consequences for human health and the economy. Therefore, a large effort has been devoted to the development of new anti-influenza virus drugs directed to viral targets, as well as to the identification of cellular targets amenable to anti-influenza virus therapy. Here we have addressed the identification of such potential cellular targets by screening collections of drugs approved for human use. We reasoned that screening with a green fluorescent protein-based recombinant replicon system would identify cellular targets involved in virus transcription/replication and/or gene expression and hence address an early stage of virus infection. By using such a strategy, we identified Montelukast (MK) as an inhibitor of virus multiplication. MK inhibited virus gene expression but did not alter viral RNA synthesis in vitro or viral RNA accumulation in vivo The low selectivity index of MK prevented its use as an antiviral, but it was sufficient to identify a new cellular pathway suitable for anti-influenza virus intervention. By deep sequencing of RNA isolated from mock- and virus-infected human cells, treated with MK or left untreated, we showed that it stimulates the PERK-mediated unfolded protein stress response. The phosphorylation of PERK was partly inhibited in virus-infected cells but stimulated in MK-treated cells. Accordingly, pharmacological inhibition of PERK phosphorylation led to increased viral gene expression, while inhibition of PERK phosphatase reduced viral protein synthesis. These results suggest the PERK-mediated unfolded protein response as a potential cellular target to modulate influenza virus infection. IMPORTANCE: Influenza A viruses are responsible for annual epidemics and occasional pandemics with important consequences for human health and the economy. The unfolded protein response is a defense mechanism fired by cells when the demand of protein synthesis and folding is excessive, for instance, during an acute virus infection. In this report, we show that influenza virus downregulates the unfolded protein response mediated by the PERK sensor, while Montelukast, a drug used to treat asthma in humans, specifically stimulated this response and downregulated viral protein synthesis and multiplication. Accordingly, we show that PERK phosphorylation was reduced in virus-infected cells and increased in cells treated with Montelukast. Hence, our studies suggest that modulation of the PERK-mediated unfolded protein response is a target for influenza virus inhibition.

Indexed as

Unfolded Protein ResponseAcetatesCyclopropaneseIF-2 KinaseHumansInfluenza A virusInfluenza, HumanPhosphorylationQuinolinesSulfidesViral ProteinsVirus ReplicationAcetatesCyclopropanesEIF2AK3 protein, humaneIF-2 KinasemontelukastQuinolinesSulfidesViral Proteins

Identifiers

PMID27094326
PMCPMC4850254
OpenAlexW2342271485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.